Avidity Biosciences Inc. (RNA) Prices 8M Share Offering at $18/sh

Pre-Open Stock Movers 08/03: (OTLK) (TBIO) (HOLI) Higher; (CLX) (RNA) (KOPN) Lower (more...)

Pre-Open Stock Movers:

Outlook Therapeutics, Inc. (Nasdaq: OTLK) 34.5% HIGHER; announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 / LYTENAVA (bevacizumab) for treatment of neovascular age-related macular degeneration (wet AMD). Outlook Therapeutics will host a conference call and webcast today, August 3, 2021, at 8:00 a.m. ET (details below) to discuss the results of the study.

Translate Bio (NASDAQ: TBIO) 29.2% HIGHER; As part of Sanofis endeavor to... More

After-Hours Stock Movers 08/02: (TBIO) (PCSA) (SEDG) Higher; (RNA) (ADUS) (SANM) Lower (more...)

After-Hours Stock Movers:

Translate Bio (NASDAQ: TBIO) 27.8% HIGHER; Sanofi (NASDAQ: SNY) made an offer to acquire Translate Bio (NASDAQ: TBIO)

Processa Pharmaceuticals (NASDAQ: PCSA) 23% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $20.00.

SolarEdge Technologies (NASDAQ: SEDG) 11% HIGHER; reported Q2 EPS of $1.28, $0.16 better than the analyst estimate of $1.12. Revenue for the quarter... More

Avidity Biosciences Inc. (RNA) Announces $100M Proposed Public Offering of Common Stock

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock... More

Avidity Biosciences Inc. (RNA) Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy

Avidity Biosciences, Inc. (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that the U.S. Food and Drug Administration (FDA) cleared the company to proceed with the Phase 1/2 MARINA clinical trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).

AOC 1001, Avidity's lead program utilizing its AOC platform, is designed to address the root cause of DM1 by reducing levels of DMPK, the disease-related mRNA. AOC 1001 consists of a proprietary monoclonal antibody that binds to the transferrin... More